Hexal Korea Launches Marketing Activities for Ethical Generics

Published: 2005-01-12 06:57:00

Updated: 2005-01-12 06:57:00

Hexal Korea, a local subsidiary of Germany's Hexal AG, has recently launched its marketing activities by introducing four pharmaceutical generic products in the domestic market SimvaHexal, LisiHexal, EnaHexal, and Fluneurin.

SimvaHexal (active ingredient: simvastatin) is for treatment of hype...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK